TR-FRET Homogeneous Time-Resolved Fluorescence Technology: Principle and Applications

I. Introduction

Homogeneous Time-Resolved Fluorescence (TR-FRET) technology is a novel detection platform that combines Time-Resolved Fluorescence (TRF) and Fluorescence Resonance Energy Transfer (FRET) core technologies. It is widely used in drug screening, life science research, and clinical diagnostics. This technique eliminates the need for separation and washing steps, enabling direct detection in liquid phase while offering high sensitivity, specificity, and repeatability, making it an ideal tool for high-throughput drug screening. This article systematically elaborates on the technical principles, core advantages, operational procedures, and application fields of TR-FRET.

II. Background of Technological Development

TR-FRET technology was developed and commercialized by a French research institution (Cisbio Bioassays) to provide high-quality detection kits for life sciences and diagnostics. Compared to traditional immunoassay methods, this technology offers users more sensitive and reliable quantitative detection results. After years of development, TR-FRET has established a comprehensive technical system, including validated drug discovery screening reagents, high-throughput analysis kits, and in vitro diagnostic kits, which are widely used in global research and industrial laboratories.

III. Technical Principles

TR-FRET technology is based on two core technologies: Time-Resolved Fluorescence (TRF) and Fluorescence Resonance Energy Transfer (FRET).

Time-Resolved Fluorescence (TRF) utilizes the unique fluorescence properties of lanthanide elements (e.g., Europium Eu, Terbium Tb) in rare earth metals. Compared to conventional fluorophores, lanthanide elements have fluorescence half-lives in the millisecond range, whereas conventional fluorophores have half-lives in the nanosecond range—a difference of six orders of magnitude. During detection, by setting a time delay of 50-150 microseconds, the background fluorescence signal from conventional sources nearly decays to zero, while the fluorescence signal from lanthanide elements can still be accurately detected. This mechanism significantly reduces background interference, ensuring that the detection results truly reflect the sample conditions.

Fluorescence Resonance Energy Transfer (FRET) leverages energy transfer between two fluorophores. When the energy donor is excited by an external light source, it can resonantly transfer energy to the acceptor if they are sufficiently close (typically 1-10 nm), causing the acceptor to emit light at a specific wavelength. By labeling the donor and acceptor onto two interacting biomolecules, respectively, when the biomolecules bind, the donor and acceptor are brought within the effective distance, generating an energy transfer signal. Since the acceptor's emission originates from energy transfer, the detection does not require separation of unbound molecules, enabling homogeneous detection.

IV. Technical Advantages

As a no-wash ELISA method, TR-FRET technology offers significant advantages. The operation is extremely simple: reagents are added directly to the plate, and after incubation, detection can be performed immediately, with the entire process taking about 2 hours. The system is highly stable, with detection signals remaining largely unchanged for up to 7 days, providing ample flexibility for experimental scheduling. It is suitable for precious samples, as the entire experimental system requires only 20 microliters of sample, greatly conserving sample usage.

As a homogeneous detection system, it eliminates the need for coating and washing steps, saving time and effort. The use of ratio-based data processing (e.g., 665nm/620nm) effectively removes background fluorescence interference, resulting in low false-positive and false-negative rates. The detection results accurately reflect the actual sample conditions, eliminating background interference caused by natural product autofluorescence and ensuring objective and reliable data.

V. Operational Procedures

The operational procedure for TR-FRET technology is straightforward. First, the required reagents—including the test sample, donor-labeled detection molecules, and acceptor-labeled detection molecules—are sequentially added to the detection plate. The reaction system is then incubated at an appropriate temperature to allow sufficient binding of biomolecules, forming donor-acceptor proximity complexes. After incubation, the fluorescence signal is directly read using a compatible detection instrument. The entire process requires no washing or separation steps, achieving a true "add-incubate-detect" three-step operation, significantly improving detection efficiency.

VI. Detection Instruments

TR-FRET technology is compatible with a wide range of instruments. Validated detection instruments include various models of multifunctional microplate readers (e.g., PerkinElmer EnVision, BMG PheraStar, Tecan Infinite series), all equipped with time-resolved fluorescence detection modules. These instruments undergo rigorous testing to ensure perfect compatibility with TR-FRET kits. Instrument suppliers and technical support teams maintain close collaboration to provide users with complete solutions, from reagent selection to data analysis.

VII. Application Fields

TR-FRET technology plays an important role in multiple research areas. In drug screening, it can be used for high-throughput screening of targets such as protein-protein interactions, kinase activity, and receptor-ligand binding. In signaling pathway research, it can detect concentration changes of second messenger molecules like cAMP and IP1. In epigenetics, it is suitable for quantitative analysis of histone modifications and DNA methylation. In immunoassays, it enables precise quantification of cytokines and biomarkers. Additionally, in PROTAC degrader development, TR-FRET technology is widely used to detect interactions between target proteins and E3 ligases.

VIII. Summary and Outlook

With its advantages of high sensitivity, specificity, and operational simplicity, TR-FRET homogeneous time-resolved fluorescence technology has become an essential tool in drug screening and life science research. As detection instruments become more compact and reagent kit varieties continue to expand, this technology will play an even greater role in point-of-care testing (POCT) and precision medicine. In the future, the integration of TR-FRET technology with microfluidics and automation platforms will further enhance detection throughput and efficiency, providing stronger support for biomedical research.